Regenicin Presentation Now Available Online at RetailInvestorConferences.com
NEW YORK, Nov. 5, 2010 /PRNewswire/ -- Regenicin, Inc. (OTC Bulletin Board: WDST) a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, today announced that their November 4th investor presentation is available for archive viewing.
Link: www.retailinvestorconferences.com
Regenicin's presentation will be available for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks.
The Regenicin presentation, which was given by CEO, Randall McCoy and CFO, John Weber, provides an overview of Regenicin's role in the development of the product candidate, PermaDerm™, an exciting breakthrough technology that uses the patient's own skin cells to generate living, tissue-engineered skin for the treatment of chronic burns. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. These living self-to-self skin graft tissue are intended to form permanent skin that will grow with the patient and not be rejected by the immune system, a critical possibility in porcine or cadaver skin grafts used today.
About RetailInvestorConferences.com
RetailInvestorConferences.com, created by BetterInvesting (NAIC), PR Newswire and MUNCmedia, is the first monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.
return to 2010 Press and News Releases
return to Home Page
About Regenicin
Regenicin, Inc. (OTC Bulletin Board: RGIN), is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world-class management team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. The company is publicly traded with headquarters in New Jersey.
Safe Harbor Statement.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE: Regenicin(TM), Inc.